Ocular Involvement in Hereditary Amyloidosis
Authors:
- Angelo Maria MinnellaAMAngelo Maria Minnella
- Roberta RissottoRRRoberta Rissotto
- Elena AntoniazziEAElena Antoniazzi
- Marco Di GirolamoMGMarco Di Girolamo
- Marco LuigettiMarco Luigetti
- Martina MaceroniMartina Maceroni
- Daniela BacheriniDaniela Bacherini
- Benedetto FalsiniBenedetto Falsini
- Stanislao RizzoStanislao Rizzo
- Laura ObiciLOLaura Obici
Open Access
Abstract
The term amyloidosis describes a group of rare diseases caused by protein conformation abnormalities resulting in extracellular deposition and accumulation of insoluble fibrillar aggregates. So far, 36 amyloid precursor proteins have been identified, and each one is responsible for a specific disease entity. Transthyretin amyloidosis (ATTRv) is one of the most common forms of systemic and ocular amyloidosis, due to the deposition of transthyretin (TTR), which is a transport protein mainly synthesized in the liver but also in the retinal pigment epithelial cells. ATTRv amyloidosis may be misdiagnosed with several other conditions, resulting in a significant diagnostic delay. Gelsolin and keratoepithelin are other proteins that, when mutated, are responsible for a systemic amyloid disease with significant ocular manifestations that not infrequently appear before systemic involvement. The main signs of ocular amyloid deposition are in the cornea, irido-corneal angle and vitreous, causing complications related to vasculopathy and neuropathy at the local level. This review aims at describing the main biochemical, histopathological and clinical features of systemic amyloidosis associated with eye involvement, with particular emphasis on the inherited forms. We discuss currently available treatments, focusing on ocular involvement and specific ophthalmologic management and highlighting the importance of a prompt treatment for the potential sight-threatening complications derived from amyloid deposition in ocular tissues.Keywords
This publication has 109 references indexed in Scilit:
- Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisNew England Journal of Medicine, 2013
- Classification of Secondary Corneal Amyloidosis and Involvement of LactoferrinOphthalmology, 2013
- Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic interventionCritical Reviews in Biochemistry and Molecular Biology, 2012
- RECURRENCE OF VITREOUS AMYLOIDOSIS AND NEED OF SURGICAL REINTERVENTION IN PORTUGUESE PATIENTS WITH FAMILIAL AMYLOIDOSIS ATTR V30MRetina, 2011
- Lipid-like materials for low-dose, in vivo gene silencingProceedings of the National Academy of Sciences of the United States of America, 2010
- Lattice corneal dystrophy, gelsolin type (Meretoja’s syndrome)Acta Ophthalmologica, 2009
- A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxiaJournal of Neurology, Neurosurgery & Psychiatry, 2007
- New mutant gene (transthyretin Arg 58) in cases with hereditary polyneuropathy detected by non-isotope method of single-strand conformation polymorphism analysisBiochemical and Biophysical Research Communications, 1991
- A novel variant of transthyretin (Tyr114 to Cys) deduced from the nucleotide sequences of gene fragments from familial amyloidotic polyneuropathy in Japanese sibling casesBiochemical and Biophysical Research Communications, 1990
- Restriction fragment analysis confirms the position 33 mutation in transthyretin from an Israeli patient (SKO) with familial amyloidotic polyneuropathyBiochemical and Biophysical Research Communications, 1988